



Financial Tear Sheet

Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology
Investor Relations
Phone: 617-588-1960
E-mail:
ir@aveooncology.com

Stock Performance

AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$2.94
Change (%)	▲ 0.03 (1.03%)
Volume	580,856
52 Week Low	\$0.50
Market Cap	\$347,876,664
Rolling EPS	-0.74
PE Ratio	N/A

Shares Outstanding 118,325,396

Data as of 02/21/18 12:45 p.m. ET



Recent Headlines

02/12/18

AVEO Announces EUSA Pharma Granted Positive NICE Recommendation for FOTIVDA® (tivozanib) as First Line Treatment for Advanced Renal Cell Carcinoma

02/10/18

AVEO Oncology and EUSA Pharma Announce Encouraging Preliminary Results from Phase 2 Portion of the TiNivo Study in Renal Cell Carcinoma

02/07/18

AVEO Oncology to Present at Upcoming Conferences

Events

DATE	TITLE
02/21/18 10:00 a.m. ET	AVEO Oncology at the RBC Capital Markets Healthcare Conference

SEC Filings

FILING DATE FORM

02/16/18	424B5
02/16/18	8-K
02/14/18	SC 13G
02/05/18	4

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed